First Tracks Biotherapeutics, Inc. 8-K

What Happened First Tracks Biotherapeutics, Inc. (TRAX) filed an 8‑K (Regulation FD disclosure) reporting that its Form 10 registration statement related to the spin-off from AnaptysBio was declared effective April 1, 2026. The company attached a final Information Statement dated April 1, 2026 (Exhibit 99.1) and AnaptysBio has begun mailing that Information Statement to its shareholders. The spin-off is expected to be effective as of 12:01 a.m. New York City time on April 20, 2026.

Key Details

• Registration Statement (Form 10) declared effective by the SEC on April 1, 2026; Information Statement dated April 1, 2026 attached as Exhibit 99.1.
• Distribution Date (expected): April 20, 2026 at 12:01 a.m. NYC time.
• Record Date: April 6, 2026 — holders of AnaptysBio common stock on that date will receive one share of First Tracks common stock for each share of AnaptysBio common stock held.
• Trading: a when‑issued market for First Tracks is expected to begin April 6, 2026 under ticker “TRAXV”; regular-way trading on Nasdaq under ticker “TRAX” is expected to begin April 20, 2026. AnaptysBio common stock is expected to trade in two lines: “ANAB” (with entitlements) and “ANABV” (ex-distribution).

Why It Matters This filing confirms the timetable and mechanics for the First Tracks spin-off, telling shareholders when they will receive shares and when trading will begin. For AnaptysBio shareholders, the Record Date and distribution ratio (1-for-1) determine eligibility and entitlement; the separate tickers and when-issued trading affect how the two companies’ shares will trade around the split. The Information Statement provides fuller details for investors about First Tracks’ business and management and has been mailed to AnaptysBio shareholders.